New England Capital Financial Advisors LLC bought a new position in Johnson & Johnson (NYSE:JNJ – Get Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,296 shares of the company’s stock, valued at approximately $556,000. Johnson & Johnson makes up about 0.4% of New England Capital Financial Advisors LLC’s investment portfolio, making the stock its 25th biggest position.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $40,000. TD Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $48,000. VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the period. 67.94% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. UBS Group assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective on the stock. Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Finally, Raymond James decreased their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.00.
Insider Buying and Selling at Johnson & Johnson
Johnson & Johnson Stock Up 0.9 %
Shares of NYSE:JNJ opened at $165.03 on Wednesday. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The company has a 50 day moving average of $158.00 and a 200-day moving average of $167.05. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The stock has a market cap of $429.79 billion, a price-to-earnings ratio of 34.53, a P/E/G ratio of 2.78 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.67 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.88%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM’s Hot Hand Is All In For A Rally, After This Small Break
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
